After 2 months of switching her treatment regimen to the 2nd generation ALK inhibitor, the regressed cystic lesions in the liver and kidneys remained unchanged (Fig. 4), and the size of primary lung cancer (approximately 2.6 × 1.9 cm) and lymph nodes on the left hilum as well as obstructive pneumonia were not changed, either. The gene discussed is ALK; the disease is lung carcinoma.